Generation Bio Co. (NASDAQ:GBIO) Short Interest Update

Generation Bio Co. (NASDAQ:GBIO) was the target of a large growth in short interest during the month of July. As of July 15th, there was short interest totalling 1,910,000 shares, a growth of 13.7% from the June 30th total of 1,680,000 shares. Approximately 3.9% of the shares of the company are short sold. Based on an average trading volume of 159,100 shares, the days-to-cover ratio is presently 12.0 days.

Wall Street Analyst Weigh In

Several research firms have commented on GBIO. Wedbush reiterated an “outperform” rating and issued a $5.00 price objective on shares of Generation Bio in a report on Tuesday, May 14th. Needham & Company LLC restated a “buy” rating and set a $10.00 price objective on shares of Generation Bio in a research report on Tuesday, May 14th. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $8.00.

Generation Bio Price Performance

Generation Bio stock traded down $0.40 during midday trading on Monday, hitting $3.11. The company’s stock had a trading volume of 75,934 shares, compared to its average volume of 218,021. Generation Bio has a 1-year low of $0.86 and a 1-year high of $5.50. The company has a 50-day moving average price of $2.94 and a two-hundred day moving average price of $2.85.

Generation Bio (NASDAQ:GBIO) last issued its quarterly earnings results on Monday, May 13th. The company reported ($1.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.76). Generation Bio had a negative net margin of 1,696.87% and a negative return on equity of 82.33%. The company had revenue of $4.06 million during the quarter, compared to the consensus estimate of $3.02 million. Analysts forecast that Generation Bio will post -1.68 EPS for the current year.

Institutional Investors Weigh In On Generation Bio

Institutional investors and hedge funds have recently bought and sold shares of the company. Bank of New York Mellon Corp boosted its holdings in shares of Generation Bio by 31.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 186,756 shares of the company’s stock valued at $527,000 after purchasing an additional 44,378 shares in the last quarter. Artal Group S.A. boosted its stake in Generation Bio by 0.6% in the first quarter. Artal Group S.A. now owns 2,830,591 shares of the company’s stock valued at $11,521,000 after buying an additional 16,400 shares in the last quarter. Baker BROS. Advisors LP bought a new position in Generation Bio in the first quarter valued at about $1,511,000. Yiheng Capital Management L.P. acquired a new position in Generation Bio during the first quarter worth about $780,000. Finally, Bellevue Group AG lifted its holdings in shares of Generation Bio by 6.8% in the first quarter. Bellevue Group AG now owns 3,861,575 shares of the company’s stock worth $15,717,000 after acquiring an additional 244,495 shares during the last quarter. Institutional investors own 95.22% of the company’s stock.

About Generation Bio

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.